{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000136","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.686479+00:00","generated_at":"2026-06-07T02:02:41.044651+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MaxCyte reports prelim Q4 total revenue $15.5-15.7M, core down YoY; FY total revenue $41.1-41.3M","bullets":["Q4 2023 total revenue expected $15.5-15.7M (Q4 2022: $12.4M); core revenue $7.0-7.2M (down from $10.6M) and SPL revenue ~$8.5M (up from $1.9M).","FY 2023 total revenue expected $41.1-41.3M (FY 2022: $44.3M); core revenue $29.6-29.8M (down from $39.6M), SPL ~$11.4M (up from $4.6M).","Cash, equivalents and investments ~$210M as of Dec 31, 2023.","Management cited Vertex CASGEVY FDA approval as milestone validating platform; core revenue decline reflects cell therapy industry headwinds.","Results are preliminary, unaudited; audited statements expected in March 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000136","json":"https://secwatch.observer/filing/0001558370-24-000136.json","markdown":"https://secwatch.observer/filing/0001558370-24-000136.md","text":"https://secwatch.observer/filing/0001558370-24-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837024000136/0001558370-24-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837024000136/mxct-20240108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:02:41.044651+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32634694baa33edf55489546ca7ea2962b4499d2","claim":"MAXCYTE, INC. reported the fourth quarter ended December 31, 2023 results: revenue between $15.5 million and $15.7 million.","evidence_excerpt":"Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000155837024000136/0001558370-24-000136-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"between $15.5 million and $15.7 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"65aad5ab31dd1e9d8ace3f8c612f92bc1a2ab955","claim":"MAXCYTE, INC. reported the fiscal year ended December 31, 2023 results: revenue between $41.1 and $41.3 million.","evidence_excerpt":"Total revenue for the fiscal year of 2023 is expected to be between $41.1 and $41.3 million, compared to $44.3 million for fiscal year 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000155837024000136/0001558370-24-000136-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"between $41.1 and $41.3 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}